Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Open Access
- 24 March 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (7) , 3559
Abstract
The prognosis of invasive cervical cancer (CC) remains poor, with a treatment approach that has remained the same for several decades. Lately, a better understanding of the interactions between the disease and the host immune system has allowed researchers to focus on the employment of immune therapy in various clinical settings. The most advanced strategy is immune checkpoint inhibitors (ICIs) with numerous phase II and III trials recently concluded with very encouraging results, assessing single agent therapy, combinations with chemotherapy and radiotherapy. Apart from ICIs, several other compounds have gained the spotlight. Tumor Infiltrating Lymphocytes (TILs) due to their highly selective tumoricidal effect and manageable adverse effect profile have received the FDA’s Breakthrough Therapy designation in 2019. The antibody drug conjugate (ADC) Tisotumab-Vedotin has shown activity in metastatic CC relapsed after at least one line of chemotherapy, with a phase III trial currently actively enrolling patients. Moreover, the deeper understanding of the ever-changing immune landscape of CC carcinogenesis has resulted in the development of active therapeutic vaccines. This review highlights the different immunotherapeutic strategies being explored reflects on what role immunotherapy might have in therapeutic algorithms of CC and addresses the role of predictive biomarkers.Keywords
Funding Information
- Università degli Studi di Torino (VALG_RILO_20_01)
This publication has 87 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Human Papillomavirus Type 8 Interferes with a Novel C/EBPβ-Mediated Mechanism of Keratinocyte CCL20 Chemokine Expression and Langerhans Cell MigrationPLOS Pathogens, 2012
- Epithelial Cell Responses to Infection with Human PapillomavirusClinical Microbiology Reviews, 2012
- Tissue factor and cell signalling in cancer progression and thrombosisJournal of Thrombosis and Haemostasis, 2011
- Clinical Applications of DNA Vaccines: Current ProgressClinical Infectious Diseases, 2011
- Differential Regulation of Human Papillomavirus Type 8 by Interferon Regulatory Factors 3 and 7Journal of Virology, 2011
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysisBMJ, 2008
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose TrialJournal of Virology, 2008